Microbix Biosystems (MBX) Q3 2025 earnings summary

Executive summary

• Q3 fiscal 2025 was the weakest in three years, with revenue falling to $3.5M, the lowest in 11 quarters, due to reduced Chinese demand and a major QAPS client halting development, resulting in a net loss of $1.64M for the quarter and $0.77M YTD loss.

• Customer concentration risk materialized, with five customers accounting for 77% of Q3 revenue and 81% of receivables, and the company unable to quickly backfill lost revenues.

• Despite setbacks, recurring sales remained stable year-over-year, and QAPs business excluding the canceled customer showed double-digit growth.

• Gross margin dropped to 41% in Q3 from 54% last year, with YTD gross margin at 56% versus 63% in YTD 2024.

• Management remains focused on resuming growth, expanding the customer base, launching new products, and leveraging strong liquidity.

Financial highlights

• Q3 2025 revenue: $3.47M, down 31% from Q3 2024; YTD revenue: $14.84M, down 22% year-over-year.

• Q3 net loss: $1.64M vs. net income of $0.25M in Q3 2024; YTD net loss: $0.77M vs. net income of $3.08M in YTD 2024.

• Margins were negatively impacted by lower sales volumes and unfavorable product mix, with Q3 gross margin at 41%.

• Loss of one-time funding and favorable financial adjustments from the prior year further affected results.

• Cash and equivalents at June 30, 2025: $12.1M; current ratio: 9.73; debt-to-equity ratio: 0.30.

Outlook and guidance

• At least one more challenging quarter is expected before recurring sales recover; management expects it will take several quarters to return to previous growth trajectory.

• New customers, products, and programs are being targeted to rebuild sales, with significant impact expected in fiscal 2026.

• QAPS segment expected to be the fastest-growing revenue source through fiscal 2027, driven by new products, regulatory changes, and PoCT adoption.

• QUANTDx product line is expected to generate under CAD 500,000 in 2026, with long-term growth potential.

• No plans for significant cost-cutting or headcount reduction; focus remains on top-line growth.